BioNTech SE (NASDAQ:BNTX) Sees Significant Decline in Short Interest

BioNTech SE (NASDAQ:BNTX) was the target of a large decrease in short interest in May. As of May 31st, there was short interest totalling 3,040,000 shares, a decrease of 11.1% from the May 15th total of 3,420,000 shares. Currently, 1.3% of the shares of the stock are short sold. Based on an average daily volume of 741,300 shares, the short-interest ratio is presently 4.1 days.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on BNTX shares. BMO Capital Markets cut their target price on BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 7th. Canaccord Genuity Group restated a “buy” rating and issued a $171.00 target price on shares of BioNTech in a report on Thursday, March 21st. JPMorgan Chase & Co. cut their target price on BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a research report on Friday, March 22nd. UBS Group dropped their price target on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a report on Wednesday, March 27th. Finally, Evercore ISI began coverage on BioNTech in a report on Tuesday, May 14th. They set an “inline” rating and a $100.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $111.70.

BioNTech Stock Performance

BioNTech stock traded down $3.92 during trading on Friday, reaching $92.08. The company had a trading volume of 768,301 shares, compared to its average volume of 984,847. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01. The firm’s 50-day simple moving average is $92.81 and its 200 day simple moving average is $95.79. The firm has a market capitalization of $21.89 billion, a price-to-earnings ratio of 184.16 and a beta of 0.27. BioNTech has a 52 week low of $85.21 and a 52 week high of $125.83.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, May 6th. The company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.60). The firm had revenue of $203.69 million for the quarter, compared to analysts’ expectations of $589.96 million. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. Sell-side analysts forecast that BioNTech will post -2.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of BNTX. CWM LLC grew its holdings in shares of BioNTech by 657.6% during the fourth quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after buying an additional 217 shares during the last quarter. GAMMA Investing LLC boosted its holdings in BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after purchasing an additional 150 shares during the last quarter. Frazier Financial Advisors LLC purchased a new stake in BioNTech in the fourth quarter valued at $30,000. Covestor Ltd purchased a new stake in BioNTech in the third quarter valued at $32,000. Finally, First Horizon Advisors Inc. purchased a new stake in BioNTech in the fourth quarter valued at $38,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.